Durable Response of Androgen Receptor-Positive Male Breast Cancer to Goserelin

Abstract

The luteinizing hormone-releasing hormone/androgen receptor (LHRH/AR) pathway is a promising treatment target in a subgroup of female patients with triple-negative breast cancer (TNBC). However, very little is known about the efficacy of this strategy in male patients with TNBC. In this report, we describe a male patient with AR-positive TNBC who was successfully treated using an LHRH agonist after pretreatment with several lines of chemotherapy and achieved a durable response. We also review the existing evidence supporting LHRH- and AR-targeted therapy for this rare disease.

Case Report: Response to Immunotherapy and Anti-Androgen Therapy in Male Occult Triple-Negative Breast Cancer

“…Notably, the AR expression rate in the current patient was >80% Figure 1C ), suggesting high dependence on AR signaling pathways for tumor survival and proliferation. One previous case report suggested a durable response of AR-positive male TNBC to goserelin ( 19 ), while another suggested a complete response of metastatic LAR TNBC to bicalutamide in a female patient ( 20 ). Notably, the AR expression rates in both these patients were 100%.…”

Neoadjuvant treatment for male breast cancer

“…There is however scant evidence of use of goserelin in MBC cases. Abdel Azim et al reported a 56-year-old male with bone metastases who achieved a year-long remission with goserelin monotherapy albeit with side-effects including grade II hot flushes and sexual dysfunction ( 14 ). Di Lauro et al treated 36 men with metastatic breast cancer using cyproterone acetate with or without goserelin ( 15 ).…”